Alsharif, Mohammed H.Alsharif, Yahia H.Albreem, Mahmoud A. M.Jahid, AbuSolyman, Ahmad Amin AhmadYahya, Khalid O. Moh.Alomari, Osama AhmadHossain, Md. Sanwar2023-08-162023-08-1620201128-3602https://hdl.handle.net/11363/5352https://doi.org/Researchers have found many similarities between the 2003 severe acute respiratory syndrome (SARS) virus and SARSCoV-19 through existing data that reveal the SARS’s cause. Artificial intelligence (AI) learning models can be created to predict drug structures that can be used to treat COVID-19. Despite the effectively demonstrated repurposed drugs, more repurposed drugs should be recognized. Furthermore, technological advancements have been helpful in the battle against COVID-19. Machine intelligence technology can support this procedure by rapidly determining adequate and effective drugs against COVID-19 and by overcoming any barrier between a large number of repurposed drugs, laboratory/clinical testing, and final drug authorization. This paper reviews the proposed vaccines and medicines for SARSCoV-2 and the current application of AI in drug repurposing for COVID-19 treatment.eninfo:eu-repo/semantics/openAccessAttribution-NonCommercial-NoDerivs 3.0 United StatesCOVID-19SARS-CoV-2CoronavirusArtificial intelligenceMachine learningArticle2422119771198110.26355/eurrev_202011_23860332752752-s2.0-85097126863Q2WOS:000594462100075Q2